Peter Dreger

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
    P Dreger
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Leukemia 21:12-7. 2007
  2. ncbi Autologous stem cell transplantation for chronic lymphocytic leukemia
    Peter Dreger
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany, and Department of Hematology, Hopital Edouard Herriot, Lyon, France
    Semin Hematol 44:246-51. 2007
  3. ncbi Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
    Peter Dreger
    Department of Medicine V, University of Heidelberg, INF 410, 69120 Heidelberg, Germany
    Haematologica 92:42-9. 2007
  4. ncbi Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
    Peter Dreger
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Blood 116:2438-47. 2010
  5. ncbi Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma
    Sascha Dietrich
    Department of Hematology, University of Heidelberg, Heidelberg, Germany
    Cancer 117:1901-10. 2011
  6. ncbi Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system
    Thomas Luft
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Blood 118:1685-92. 2011
  7. ncbi Autologous transplant of follicular lymphoma in the era of rituximab
    Mathias Witzens-Harig
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Leuk Lymphoma 51:967-74. 2010
  8. ncbi Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity
    Sascha Dietrich
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Biol Blood Marrow Transplant 17:1250-4. 2011
  9. ncbi Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial
    Mathias Witzens-Harig
    Department of Internal Medicine V, University Hospital of Heidelberg, INF 410, 69120 Heidelberg, Germany
    Ann Hematol 88:51-7. 2009
  10. ncbi Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?
    Leopold Sellner
    Department of Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany
    Curr Hematol Malig Rep 7:3-12. 2012

Detail Information

Publications31

  1. ncbi Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
    P Dreger
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Leukemia 21:12-7. 2007
    ....
  2. ncbi Autologous stem cell transplantation for chronic lymphocytic leukemia
    Peter Dreger
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany, and Department of Hematology, Hopital Edouard Herriot, Lyon, France
    Semin Hematol 44:246-51. 2007
    ..A significant risk of secondary neoplasms, in particular myelodysplasias, has to be taken into account. Therefore, ASCT cannot be considered as standard treatment for CLL and should be performed only in the context of clinical trials...
  3. ncbi Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
    Peter Dreger
    Department of Medicine V, University of Heidelberg, INF 410, 69120 Heidelberg, Germany
    Haematologica 92:42-9. 2007
    ..Autologous stem cell transplantation (ASCT) is effective in mantle cell lymphoma (MCL). We investigated whether incorporation of rituximab into the high-dose regimen might further improve the results of ASCT in patients with MCL...
  4. ncbi Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
    Peter Dreger
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Blood 116:2438-47. 2010
    ..This trial is registered at http://clinicaltrials.gov as NCT00281983...
  5. ncbi Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma
    Sascha Dietrich
    Department of Hematology, University of Heidelberg, Heidelberg, Germany
    Cancer 117:1901-10. 2011
    ..Autologous stem cell transplantation (autoSCT) has improved the outcome of patients with mantle cell lymphoma (MCL) considerably. However, little is known about the patterns and outcome of MCL recurrence after autoSCT...
  6. ncbi Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system
    Thomas Luft
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Blood 118:1685-92. 2011
    ..These results suggest that endothelial cell vulnerability and dysfunction, rather than refractory T-cell activity, drives treatment refractoriness of GVHD and opens new avenues for prediction and control of this devastating condition...
  7. ncbi Autologous transplant of follicular lymphoma in the era of rituximab
    Mathias Witzens-Harig
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Leuk Lymphoma 51:967-74. 2010
    ..However, these considerations are largely based on retrospective analyses and should be confirmed in prospective randomized trials...
  8. ncbi Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity
    Sascha Dietrich
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Biol Blood Marrow Transplant 17:1250-4. 2011
    ....
  9. ncbi Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial
    Mathias Witzens-Harig
    Department of Internal Medicine V, University Hospital of Heidelberg, INF 410, 69120 Heidelberg, Germany
    Ann Hematol 88:51-7. 2009
    ..We conclude that rituximab maintenance therapy seems to be safe and does not impair quality of life in this patient population...
  10. ncbi Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?
    Leopold Sellner
    Department of Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany
    Curr Hematol Malig Rep 7:3-12. 2012
    ..This review summarizes the most important prognostic and predictive factors in CLL, with particular emphasis on factors affecting treatment decisions in clinical trials and routine practice...
  11. ncbi Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis
    P Dreger
    Department of Hematology, Allgemeines Krankenhaus St Georg, Hamburg, Germany
    Leukemia 19:1029-33. 2005
    ..65 (0.33-1.28); P=0.21). We conclude that RIC appears to favorably influence TRM after allo-SCT for CLL. This observation, as well as possible detrimental effects of RIC on relapse risk, should be confirmed by prospective studies...
  12. ncbi Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells
    Sascha Dietrich
    Department of Medicine V, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Clin Cancer Res 18:417-31. 2012
    ..This situation can be mimicked by in vitro stimulation with CD40 ligand (CD40L) and interleukin 4 (IL-4). Our study investigates the impact of the drug leflunomide to overcome apoptosis resistance of CLL cells...
  13. ncbi Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma
    Peter Dreger
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Biol Blood Marrow Transplant 14:100-7. 2008
    ..This review summarizes the current role of HCT for patients with MCL in first remission and for patients with PTCL as consolidation and for relapsed/refractory disease...
  14. ncbi IFN-? activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production
    Michael Conzelmann
    German Cancer Research Center, Department of Molecular Oncology Hematology, Heidelberg, Germany
    Biochem Pharmacol 80:2074-86. 2010
    ..This suggests that a number of CD40 effects in chronic inflammatory diseases might be weakened by targeting JAK/STAT...
  15. ncbi Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease
    Thomas Luft
    Department Medicine V, University of Heidelberg, Heidelberg, Germany
    Blood 110:4535-42. 2007
    ..Prospective studies are warranted to evaluate how CK18Fs may assist in the diagnosis, grading, and treatment guidance of GVHD...
  16. ncbi The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry
    M Michallet
    Department of Hematology, Edouard Herriot Hospital, Lyon, France
    Leukemia 24:1725-31. 2010
    ..Our findings support the use of WMUD as equivalent alternative to HLA-matched sibling donors for allogeneic HSCT in CLL, and justify the application of EBMT risk score in this disease...
  17. ncbi Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up
    M Kornacker
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Ann Oncol 20:722-8. 2009
    ..Pattern and outcome of disease recurrence after autologous stem-cell transplantation (autoSCT) for follicular lymphoma (FL) is not well known...
  18. ncbi Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias
    M Michallet
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Br J Haematol 108:595-601. 2000
    ..However, attention should be given to the timing of mobilization with respect to the time since the last dose of fludarabine...
  19. ncbi Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease
    Alexander Claviez
    Department of Pediatrics and Bone Marrow Transplant Unit, University of Kiel, Schwanenweg 20, 24105 Kiel, Germany
    Ann Hematol 83:237-41. 2004
    ..Allogeneic PBSCT, with reduced intensity conditioning, may be beneficial for selected patients with refractory HD...
  20. ncbi Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR
    Matthias Ritgen
    Second Department of Internal Medicine, Chemnitzstr 33, D 24116 Kiel, Germany
    Blood 104:2600-2. 2004
    ..Taken together, this study shows for the first time that GVL-mediated immunotherapy might be effective in CLL with unmutated V(H)...
  21. ncbi Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis
    Johannes Schetelig
    University Hospital Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany
    J Clin Oncol 26:5094-100. 2008
    ..Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p-CLL...
  22. ncbi Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia
    Thorsten Zenz
    Department of Internal Medicine III, University of Ulm, Robert-Koch-Strasse 8, D-89081 Ulm, Germany
    Blood 108:2127-30. 2006
    ..However, the addition of alemtuzumab led to improved disease control at the molecular level. Longer follow-up will show whether the GVHD-like syndrome may contribute to prolonged minimal residual disease (MRD) negativity...
  23. ncbi Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
    Christiane Pott
    Second Medical Department, University Hospital Schleswig Holstein, Campus Kiel, Chemnitzstr 33, 24116 Kiel, Germany
    Blood 107:2271-8. 2006
    ..We conclude that sequential quantitative monitoring of residual disease after ASCT is a powerful indicator for treatment outcome in MCL and defines subgroups of patients with a significantly different prognosis...
  24. ncbi Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia
    Peter Dreger
    Biol Blood Marrow Transplant 13:623-4. 2007
  25. ncbi Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial
    M Ritgen
    Department of Medicine II, University of Schleswig Holstein, Kiel, Germany
    Leukemia 22:1377-86. 2008
    ..However, in a significant proportion of cases, this does not translate into sustained disease control due to development of secondary GVL resistance...
  26. ncbi Allogeneic transplantation in lymphoma: current status
    Norbert Schmitz
    Department of Hematology and Stem Cell Transplantation, Asklepios Klinik St Georg, Lohmühlenstr 5, D 20099 Hamburg, Germany
    Haematologica 92:1533-48. 2007
    ..Large prospective studies in well-defined entities are necessary to further clarify the role of allo-SCT in lymphoma...
  27. ncbi The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status
    Peter Dreger
    Department of Hematology, Allgemeines Krenkenhaus St Georg, Hamburg, Germany
    Blood 103:2850-8. 2004
    ..38, P=.04) as well as from study entry (HR 0.38, P=.03). These data suggest a survival benefit for patients with poor-risk CLL receiving SHDT during the course of their disease...
  28. ncbi Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells
    Matthias Zeis
    General Hospital St Georg, Hamburg, Germany
    J Immunol 170:5391-7. 2003
    ..Our data provide evidence for the use of survivin as a target structure for immunotherapeutic strategies against hematological neoplasms...
  29. ncbi Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia
    Matthias Ritgen
    Second Department of Medicine, University of Kiel, Germany
    Blood 101:2049-53. 2003
    ..Nevertheless, the hitherto only 3 deaths and the median treatment-free interval of 49 months in the unmutated cohort suggest a beneficial effect of SCT for this high-risk population in comparison to conventional treatment...
  30. ncbi Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies
    Sandra Siegel
    General Hospital St Georg, Department of Hematology, Hamburg, Germany
    J Immunol 176:6935-44. 2006
    ..The identification of OFA-iLR-derived peptide epitopes provides a basis for tumor immunological studies and therapeutic vaccination strategies in patients with OFA-iLR-expressing malignancies...
  31. ncbi Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease
    Christiane Pott
    Second Medical Department, University of Schleswig Holstein, Campus Kiel, Germany
    Eur J Haematol 74:353-8. 2005
    ....